BioSpace News Archive

RefleXion Medical, Inc. today announced that Todd Powell, president and chief executive officer, Sam Mazin, Ph.D., founder and chief technology officer, and Sean Shirvani, M.D., chief medical officer will present an overview of the company and its breakthrough SCINTIX biology-guided radiotherapy at the Jeffries Global Healthcare Conference on Wednesday, June 5 at 8:30 a.m. EDT.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor conferences in the United States and Europe during June 2024.

Quell Therapeutics Ltd announces that it is advancing QEL-001, its autologous engineered CAR-Treg cell therapy, into the efficacy cohort of the LIBERATE Phase 1/2 trial in liver transplant patients.

ZSFab Inc., a leading expert in digitally structured materials and 3D printed orthopedic devices, proudly announces the first clinical utilization of its recently launched InterConnect™ 3D Printed Ti Lumbar Interbody System.

MetaDeq Ltd. announced that two posters will be presented at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

Rosalind Franklin University of Medicine and Science research faculty have been named among “Illinois Researchers to Know” by the Illinois Science and Technology Coalition. The annual list recognizes the groundbreaking work of scientists and ten institutions driving innovation in the state.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

The Sickle Cell Disease Foundation (SCDF) is proud to announce a research collaboration agreement (RCA) with the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) to develop best practices for the safe and effective use of artificial intelligence (AI) and machine learning (ML) systems and digitally-derived measures that matter to patients.

TELA Bio, Inc. announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson’s MedTech Segment, to its Board of Directors, effective June 4, 2024.

Celldex Therapeutics, Inc. announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET.